ABVC BioPharma Announces 2024 Financial Results
ABVC BioPharma Announces 2024 Financial Results https://abvcpharma.com/wp-content/themes/movedo/images/empty/thumbnail.jpg 150 150 Press Release https://secure.gravatar.com/avatar/16e1fb99bcbeb5306557b18c84c6454051e7fb0924dd51867e73dc4cd6833b54?s=96&d=mm&r=gSilicon Valley, CA (April 15, 2025) ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, leveraging its asset-light, partnership-driven model, today announced its financial results for the fiscal year ended December 31, 2024, marking a pivotal year of operational transformation and financial improvement. Revenue Growth of 234% Fueled by Global Licensing Milestones ABVC reported total revenues of $509,589 in 2024, representing a 234% increase compared to $152,430 in 2023. This significant growth was primarily driven by milestone payments collected from the Company’s global licensing partners in CNS, oncology, and ophthalmology…